<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856075</url>
  </required_header>
  <id_info>
    <org_study_id>Sanofi-EFFECT-AF</org_study_id>
    <nct_id>NCT01856075</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Atrial Fibrillation</brief_title>
  <acronym>EFFECT-AF</acronym>
  <official_title>Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La-ser Europe Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La-ser Europe Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international observational multicentre study to be conducted in Germany, Spain,
      Italy and USA. The main objective of the study is to evaluate the relative effectiveness of
      dronedarone in real world clinical practice versus other anti-arrhythmic agents of interest.
      The design of the study is a historic-prospective cohort with dynamic exposure and stratified
      competitive recruitment with balanced comparison groups of dronedarone versus alternative
      antiarrhythmic drugs of interest.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Recurrence of Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
    <description>Assessment of the recurrence of atrial fibrillation (change from baseline) at 3 month, 6 month, and 12-18 month of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Cardiovascular hospitalisation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline AV node ablation and catheter ablation for Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Progression to permanent Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Clinical progression to heart failure and left ventricular systolic dysfunction</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Congestive heart failure</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Interstitial pulmonary disease</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Liver injury/toxicity</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Renal insufficiency/failure</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Cerebrovascular accident/Stroke</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Myocardial infarction</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Torsade de pointes</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
    <description>Assessed at each follow-up: 3 month, 6 month, and 12-18 month</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1015</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients treated with dronedarone</arm_group_label>
    <description>Patients treated with dronedarone at inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with other antiarrhythmic drugs of interest</arm_group_label>
    <description>The antiarrhythmic drugs of interest to which dronedarone will be compared are:
Class 1a/1c antiarrhythmics
Sotalol
Amiodarone</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is an international observational multicentre study to be conducted in the following
        four countries: Germany, Spain, Italy and USA. Patients will be will be recruited from
        cardiology clinics, both hospital and non-hospital based, depending on particulars of
        treatment pathway of ppAF patients in each country.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years old or above

          -  Patient with paroxysmal or persistent atrial fibrillation

          -  Patient using an AAi (antiarrhythmic drug of interest) or dronedarone (index drug)

          -  Patient's treatment changed from one AAi to another AAi or dronedarone OR from no
             antiarrhythmic therapy to the start of AAi or dronedarone therapy during previous 6
             months before the date of recruitment

          -  Patient with at least 6 months of medical and treatment information prior to the start
             of the index drug

          -  Patient able to answer the telephone interview in a language of the participating
             country: English, German, Italian or Spanish (with or without proxy).

        Exclusion Criteria:

          -  Patient with heart failure (NYHA class IV)

          -  Patient with permanent Atrial Fibrillation

          -  Patient with psychiatric conditions preventing the participation to the study
             according to the physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Artak Khachatryan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LA-SER Europe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis fuer Kardiologie, Im Muehlenbach 2B</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Dronedarone</keyword>
  <keyword>Cohort</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

